Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York ...

April 18, 2024 Weight-loss drug developer Metsera raises $290 million in funding Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture ...

Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York ...